MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

This study is looking for adults aged 18 or older who have been diagnosed with multiple myeloma. You would be considered if your multiple myeloma has come back or didn't respond well to your previous treatments, including certain common medications for this condition. We also need to see signs that your multiple myeloma is still active and measurable.

There are also some health checks to make sure the study treatment is suitable and safe for you. For example, your general health, as assessed by a doctor, should be good enough to participate. You shouldn't be pregnant or breastfeeding and must agree to use contraception during the study.

Some conditions might mean you can't join, such as having other serious health problems, specific types of multiple myeloma that are not the focus of this study, or recent stem cell transplants. Also, if you've already received similar types of new treatments to elranatamab, you might not be eligible. The study team will review all your medical information carefully to see if this study is right for you.

If you join this study, you'll be assigned to one of two groups. Half of the participants will receive elranatamab, which is given as a shot under the skin. Initially, you'll get this shot about once a week at the study clinic, though this might happen less often later on. The other half will receive a combination of 2 or 3 standard multiple myeloma medicines. These can be taken by mouth at home or at the clinic, or given as a shot under the skin, or through a needle in your vein, depending on the medicines chosen for you.

You will continue to receive the study treatment as long as your multiple myeloma is responding to it. You'll have regular visits to the study clinic so the medical team can monitor your health and how the treatment is working. This will involve regular check-ups and possibly blood tests or other assessments. Even after you stop the study treatment, the team will keep in touch with you, either by phone or through follow-up visits, to see how you are doing overall. The total duration of your participation will vary depending on your individual response, but follow-up can continue for a long time.